DaVita Inc. (DVA)

DaVita's stock experienced a 5.6% decline in February 2026 due to profit-taking and concerns regarding reimbursement risk, despite strong fourth-quarter performance. In the same month, DVA reached new all-time highs due to an upward revision in its 2026 earnings guidance. In May 2026, DaVita reported strong first-quarter results, exceeding forecasts and raising its full-year guidance, initially leading to a 3.15% decline in aftermarket trading, but later a 19.4% jump on May 6, 2026. Over the last 12 months, DVA has significantly outperformed the S&P 500.

DaVita's products and services experience demand seasonality. The first quarter typically sees a seasonal softness for dialysis providers, with patient care costs per treatment declining from the seasonally high fourth quarter. The company benefits from seasonal factors such as more patients meeting their co-insurance and deductibles.

DaVita, Inc. is a healthcare company focused on kidney care services, particularly chronic kidney disease (CKD) and end-stage renal disease (ESRD). The company operates in the Dialysis and Healthcare Equipment & Services industries, providing in-center hemodialysis, home dialysis support, and related lab services. DaVita also offers integrated kidney care (IKC) services, clinical research programs, physician services, and a nephrology-specific Electronic Health Record (EHR) system.

DaVita has a global presence with outpatient dialysis centers in the United States and 14 other countries. As of March 31, 2026, it served approximately 296,300 patients across 3,262 centers worldwide, including 2,666 in the U.S. and 596 internationally. Its international operations extend to countries such as Saudi Arabia, Brazil, China, Colombia, Malaysia, Germany, Great Britain, Portugal, Poland, Singapore, Chile, Ecuador, and Japan. DaVita International's headquarters, located in London, provides strategic and operational support for its thousands of teammates outside the U.S.

DaVita's brand reputation was negatively impacted by a ransomware attack in April 2025, which led to the leakage of personal and medical data belonging to 2.7 million patients. Despite this, DaVita has a long-standing reputation for clinical quality and innovation in kidney care, and has been recognized for its sustainability efforts, including being listed on the Dow Jones Sustainability Indices (DJSI) World Index in 2016 and aiming to match 100% of its global electricity use with renewable energy purchases by 2025.

DaVita's ownership is mainly institutional, with Berkshire Hathaway Inc. holding approximately 44.98% of shares as of January 2026. Other major institutional owners include The Vanguard Group, Inc. (5.96%), BlackRock Institutional Trust Company, N.A. (3.39%), Invesco Capital Management LLC (1.98%), and State Street Investment Management (US) (2.60%). CEO Javier Rodriguez holds approximately 1.1% of the company's shares as of April 2025.